Preface

F R O M R E S E A R C H T O P R A C T I C E
I n 1922, the first insulin was made available for human use. The discovery and use of insulin revolutionized diabetes treatment and improved life for people with diabetes, especially those with type 1 diabetes. Nearly 95 years later, insulin remains the mainstay of treatment for type 1 diabetes and gestational diabetes mellitus and is also used for many people with type 2 diabetes. The evolution of insulin has continued through the years. There are now more than 15 insulin products in the U.S. market, with more in the pipeline. In the past century, new formations and delivery systems have become available that have improved the pharmacokinetics, pharmacodynamics, and ease of use of insulin for patients. In a recent article in Diabetes Care, Cefalu et al. (1) used the analogy of insulin as the "essential black dress," referring to a standard clothing item in almost every woman's closet. Similar to the black dress, insulin will never be out of fashion, can go with almost anything (from a pharmacotherapy combination perspective), and, with simple additions or modifications, can be adapted for any occasion (type of diabetes) to help patients reach their treatment goals.
As the expansion of the diabetes pharmacotherapeutic armamentarium progresses, I am honored to serve as the guest editor of this Diabetes Spectrum From Research to Practice section focusing on the advancement of contemporary insulin therapy. In the past year alone, new "concentrated" or "low-volume" insulins have Given the nearly 95-year history of insulin, this treatment remains underutilized and is often used inefficiently. Much like the "essential black dress" in many women's closets, insulin remains a basic need in the diabetes pharmacotherapy armamentarium. Health care providers must realize that, for many patients, insulin itself is not the problem; rather, accessing and understanding the importance of insulin is the problem. I hope this From Research to Practice section and the related articles elsewhere in this issue of Diabetes Spectrum will allow practitioners to explore, understand, and use modern insulin therapy effectively and proficiently in practice to provide optimal care and management to their patients with diabetes.
I wish to thank all of the outstanding authors and reviewers and the extraordinary editorial staff at Diabetes Spectrum for their hard work, dedication, and commitment to this important project. They truly have been the best team a guest editor could have.
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